SG11201809499UA - Processes for preparing phosphorodiamidate morpholino oligomers - Google Patents

Processes for preparing phosphorodiamidate morpholino oligomers

Info

Publication number
SG11201809499UA
SG11201809499UA SG11201809499UA SG11201809499UA SG11201809499UA SG 11201809499U A SG11201809499U A SG 11201809499UA SG 11201809499U A SG11201809499U A SG 11201809499UA SG 11201809499U A SG11201809499U A SG 11201809499UA SG 11201809499U A SG11201809499U A SG 11201809499UA
Authority
SG
Singapore
Prior art keywords
street
international
cambridge
processes
pct
Prior art date
Application number
SG11201809499UA
Inventor
Bao Cai
Mitchell Martini
Ross Shimabuku
Katie Thomas
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of SG11201809499UA publication Critical patent/SG11201809499UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 11111111111111111111111111111111111111111111111111111111111111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/205513 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: CO7F 9/6558 (2006.01) CO7F 9/6561 (2006.01) (21) International Application Number: PCT/US2017/034284 (22) International Filing Date: 24 May 2017 (24.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/340,953 24 May 2016 (24.05.2016) US 62/357,134 30 June 2016 (30.06.2016) US (71) Applicant: SAREPTA THERAPEUTICS, INC. [US/US]; 215 First Street, Cambridge, MA 02142 (US). (72) Inventors: CAI, Bao; c/o Sarepta Therapeutics, Inc., 215 _ First Street, Cambridge, MA 02142 (US). MARTINI, Mitchell; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US). SHIMABUKU, Ross; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA — 02142 (US). THOMAS, Katie; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US). = = Agent: TRINQUE, Brian, C. et al.; Lathrop & Gage, LLP, 28 State Street, Boston, MA 02109 (US). (74) Designated States (unless otherwise indicated, for every (81) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, — = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, = MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, = = PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, = TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, — TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, — 1-1 KM, ML, MR, NE, SN, TD, TG). M Published: ,-1 — in in with international search report (Art. 21(3)) 0 ei N (54) Title: PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS 1-1 0 (57) : Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described ei herein may be advantageous to scaling up oligomersynthesis while maintaining overall yield and purity of a synthesized oligomer.
SG11201809499UA 2016-05-24 2017-05-24 Processes for preparing phosphorodiamidate morpholino oligomers SG11201809499UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340953P 2016-05-24 2016-05-24
US201662357134P 2016-06-30 2016-06-30
PCT/US2017/034284 WO2017205513A1 (en) 2016-05-24 2017-05-24 Processes for preparing phosphorodiamidate morpholino oligomers

Publications (1)

Publication Number Publication Date
SG11201809499UA true SG11201809499UA (en) 2018-12-28

Family

ID=59078166

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809499UA SG11201809499UA (en) 2016-05-24 2017-05-24 Processes for preparing phosphorodiamidate morpholino oligomers

Country Status (16)

Country Link
US (2) US10961262B2 (en)
EP (1) EP3464306B1 (en)
JP (1) JP6987081B2 (en)
KR (1) KR102504759B1 (en)
CN (1) CN109311920B (en)
AU (1) AU2017271524B2 (en)
BR (1) BR112018074270B1 (en)
CA (1) CA3024182A1 (en)
CO (1) CO2018013827A2 (en)
IL (1) IL263033B2 (en)
MA (1) MA45155A (en)
MX (1) MX2018014162A (en)
SA (1) SA518400462B1 (en)
SG (1) SG11201809499UA (en)
TW (1) TWI737736B (en)
WO (1) WO2017205513A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (en) 2010-09-01 2016-07-11 日本新藥股份有限公司 Antisense nucleic acid
MX2018014472A (en) 2016-05-24 2019-05-23 Sarepta Therapeutics Inc Processes for preparing oligomers.
US10961262B2 (en) 2016-05-24 2021-03-30 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA45362A (en) * 2016-05-24 2019-04-10 Sarepta Therapeutics Inc PROCESSES FOR THE PREPARATION OF MORPHOLINO OLIGOMERS OF PHOSPHORODIAMIDATE
CN109152775B (en) * 2016-06-30 2022-04-26 萨勒普塔医疗公司 Process for preparing phosphoric acid diamide morpholino oligomer
CA3024153A1 (en) * 2016-06-30 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
US20200362339A1 (en) * 2017-09-25 2020-11-19 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis
CN109704980B (en) * 2019-02-16 2022-05-13 安徽大学 Preparation method of (Z) -3-amino-2- (2-fluoro-3-methoxyphenyl) -2-ethyl crotonate
WO2021187392A1 (en) * 2020-03-16 2021-09-23 国立大学法人東京医科歯科大学 Heteronucleic acid containing morpholino nucleic acid
CA3233308A1 (en) * 2021-11-01 2023-05-04 Timothy Weeden Muscle targeting complexes for treating dystrophinopathies

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
JP3022967B2 (en) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド Stereoregular polynucleotide binding polymer
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
AU4225889A (en) 1988-09-01 1990-04-02 Forskningscenter Riso Peptide synthesis method and solid support for use in the method
CN1046724C (en) * 1993-12-29 1999-11-24 藤泽药品工业株式会社 Novel compound
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
CA2372085C (en) 1999-05-04 2009-10-27 Exiqon A/S L-ribo-lna analogues
KR20020097241A (en) 2000-05-04 2002-12-31 에이브이아이 바이오파마 인코포레이티드 Splice-region antisense composition and method
AU2002334307A1 (en) 2001-09-04 2003-03-18 Exiqon A/S Novel lna compositions and uses thereof
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
WO2004043978A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US7759513B2 (en) 2003-02-21 2010-07-20 Nigu Chemie Gmbh Photolabile protective groups for improved processes to prepare oligonucleotide arrays
PL1766010T3 (en) 2004-06-28 2011-07-29 Univ Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
WO2009064471A1 (en) 2007-11-15 2009-05-22 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
DK2417257T3 (en) 2009-04-10 2016-06-06 Ass Inst De Myologie TRICYCLO DNA ANTISENSE OLIGONUCLEOTIDES, COMPOSITIONS, AND PROCEDURES FOR THE TREATMENT OF DISEASE
CA2780563A1 (en) 2009-11-12 2011-05-19 The University Of Western Australia Antisense molecules and methods for treating pathologies
JP2013530154A (en) * 2010-05-28 2013-07-25 サレプタ セラピューティクス， インコーポレイテッド Oligonucleotide analogues having modified intersubunit linkages and / or end groups
TWI463423B (en) 2010-05-28 2014-12-01 Poynt Corp Method of using location information for advertising system based on 3-dimensional shapes
TWI541024B (en) * 2010-09-01 2016-07-11 日本新藥股份有限公司 Antisense nucleic acid
WO2012043730A1 (en) 2010-09-30 2012-04-05 日本新薬株式会社 Morpholino nucleic acid derivative
WO2012109296A1 (en) * 2011-02-08 2012-08-16 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Antisense oligonucleotides
CN103889999B (en) 2011-08-23 2021-06-01 皇家学习促进学会/麦吉尔大学 Ion labeling for oligoribonucleotide synthesis
PL2581448T3 (en) 2011-10-13 2015-08-31 Association Inst De Myologie Tricyclo-phosphorothioate DNA
CN111808135A (en) 2011-11-18 2020-10-23 萨勒普塔医疗公司 Functionally modified oligonucleotides and subunits thereof
CA2857664A1 (en) 2011-11-30 2013-06-06 Sarepta Therapeutics, Inc. Antisense oligonucleotides targeting within the smn2 pre-mrna for use ininduced exon inclusion in spinal muscle atrophy
RU2619184C2 (en) * 2011-12-28 2017-05-12 Ниппон Синяку Ко., Лтд. Antisense nucleic acids
EP3287531B1 (en) 2012-02-28 2019-06-19 Agilent Technologies, Inc. Method for attaching a counter sequence to a nucleic acid sample
CN102702265A (en) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 Phosphorodiamidate morpholino oligomer synthetized by solid phase and method thereof
SI2970964T1 (en) * 2013-03-14 2019-05-31 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
EA035882B1 (en) * 2013-03-14 2020-08-27 Сарепта Терапьютикс, Инк. Antisense oligonucleotides inducing exon skipping for treating muscular dystrophy
US8999152B2 (en) * 2013-03-15 2015-04-07 Uop Llc Process and apparatus for recovering and blending hydroprocessed hydrocarbons and composition
CN105307723A (en) 2013-03-15 2016-02-03 萨勒普塔医疗公司 Improved compositions for treating muscular dystrophy
CN105228999B (en) * 2013-05-24 2021-03-02 味之素株式会社 Process for preparing morpholino oligonucleotides
MX2018014472A (en) * 2016-05-24 2019-05-23 Sarepta Therapeutics Inc Processes for preparing oligomers.
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
SG10202101836TA (en) 2016-05-24 2021-03-30 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
MA45362A (en) * 2016-05-24 2019-04-10 Sarepta Therapeutics Inc PROCESSES FOR THE PREPARATION OF MORPHOLINO OLIGOMERS OF PHOSPHORODIAMIDATE
US10961262B2 (en) * 2016-05-24 2021-03-30 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
RS63610B1 (en) 2016-12-19 2022-10-31 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy

Also Published As

Publication number Publication date
EP3464306B1 (en) 2024-03-27
US10961262B2 (en) 2021-03-30
IL263033A (en) 2018-12-31
AU2017271524A1 (en) 2018-11-15
CO2018013827A2 (en) 2018-12-28
WO2017205513A1 (en) 2017-11-30
BR112018074270B1 (en) 2021-02-02
KR20190013844A (en) 2019-02-11
CA3024182A1 (en) 2017-11-30
KR102504759B1 (en) 2023-02-28
US20190276480A1 (en) 2019-09-12
JP6987081B2 (en) 2021-12-22
JP2019523754A (en) 2019-08-29
TWI737736B (en) 2021-09-01
IL263033B2 (en) 2023-02-01
CN109311920A (en) 2019-02-05
US20220340605A1 (en) 2022-10-27
EP3464306A1 (en) 2019-04-10
BR112018074270A2 (en) 2019-03-12
CN109311920B (en) 2021-11-09
SA518400462B1 (en) 2022-06-12
MA45155A (en) 2019-04-10
TW201825506A (en) 2018-07-16
AU2017271524B2 (en) 2021-06-24
IL263033B (en) 2022-10-01
MX2018014162A (en) 2019-04-01

Similar Documents

Publication Publication Date Title
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201909949XA (en) Targeted immunotolerance
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201903487SA (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
SG11201804934PA (en) Novel Compounds
SG11201808990QA (en) Compositions for topical application of compounds
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201804774YA (en) Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201810143PA (en) Exon skipping oligomers for muscular dystrophy
SG11201808221QA (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201809502YA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809630RA (en) Nicotine particles
SG11201810352XA (en) New antibacterial compounds
SG11201810123SA (en) Treatment of intrahepatic cholestatic diseases
SG11201807478QA (en) Methods and compositions for increased double stranded rna production
SG11201809494VA (en) Pharmaceutical composition comprising eteplirsen
SG11201809031XA (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function